Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
64Cu-LNTH-1363S · 1 trial · 6 indications
Time Activity Curves (TACs) describing percentage of the injected activity versus time will be derived for selected organs and tumor lesions and absorbed radiation doses of 64Cu-LNTH-1363S in critical organs (e.g., kidneys, liver) will be estimated.
Optimal dose (radioactivity) and imaging time window will be determined by using image quality scores from blinded central reviews. Each patient will receive 8 ± 1 mCi of 64Cu-LNTH-1363S. The raw data of each patient PET scan will be re-processed using a computer program to simulate scans of the same patient with lower injected activities (6 mCi and 4 mCi).
Correlation of 64Cu-LNTH-1363S biodistribution with FAP expression by IHC (SUVmean and SUVmax vs IHC score) and compare to circulating FAP in blood as analyzed by ELISA method.
| Arm | Type | Description |
|---|---|---|
| Experimental Part 1 | EXPERIMENTAL | 6 patients will receive 8 ± 1 mCi (\~90 μg mass dose) of the 64Cu-LNTH-1363S on Day 1 in the Intervention Period (raw data of each patient PET scan will be re-processed using a computer program to simulate scans of the same patient with 6 mCi and 4 mCi 64Cu injected activities). |
| Experimental Part 2 | EXPERIMENTAL | First 6 evaluable patients will receive the optimal radioactivity determined in Part 1. The remaining 14 evaluable patients will receive either the optimal radioactivity determined in Part 1 (if the sum of the average image quality scores of the first 6 patients is higher or equal to 10.5), or 8 ± 1 mCi (if the sum of the average image quality scores of the first 6 patients is less than 10.5). |
| Name | Type | Description |
|---|---|---|
| 64Cu-LNTH-1363S | COMBINATION_PRODUCT | 64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging, |
Inclusion Criteria: Part 1 Patients are eligible to be included in the study only if all of the following criteria apply: 1. Patient must be ≥ 15 years of age and must have provided written informed consent and assent, where applicable (by patient or legal guardian). Those aged ≥15 to \<18 years m...
Top 20 of 31 competitors
64Cu-LNTH-1363S is an investigational small molecule being studied for use in metastatic sarcoma. It is a copper-64 labeled compound that targets fibroblast activation protein (FAP), which is expressed in certain tumors. The drug is currently in Phase 1 clinical development for this indication.
64Cu-LNTH-1363S targets fibroblast activation protein (FAP), a protein found on the surface of certain cells in the tumor microenvironment. By binding to FAP, the copper-64 labeled small molecule may enable imaging or delivery of therapy to FAP-expressing tumors, including metastatic sarcoma.
64Cu-LNTH-1363S is being developed by Lantheus Holdings, Inc., a company traded on the NASDAQ under the ticker symbol LNTH. The company is conducting clinical research on this investigational agent for oncology applications.
64Cu-LNTH-1363S is in Phase 1 clinical development. It is an investigational drug that has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to evaluate the drug in patients with certain cancers, including metastatic sarcoma.
64Cu-LNTH-1363S is being studied in a Phase 1 clinical trial registered as NCT06298916. This trial is recruiting 26 participants with metastatic sarcoma or gastrointestinal tract cancers, including esophageal, gastric, pancreatic, and colorectal cancer. The study is being conducted in the United States and is currently recruiting patients aged 15 years and older.